Are biotech obesity drug development company analysts highly evaluated?

新divOP : It's not a big company like Eli Lilly or Novo Nordisk, clinical trials of obesity treatment drugs and obesity treatment injections,
A manufacturer that has been promoted as a result of research and development.
No sales?
Has it been raised this year due to analysts' expectations?
A company listed on the NASDAQ.

pinkotu : Is it gambling because there are no sales?

新divOP : Are the analysts' assessments really correct?
I'm scared.
No sales? It is sold with approval
Eli Lilly is different from Novo Nordisk
If you're only raising expectations,
There is a risk that it will become a locust brand.
This stock rose instantaneously in February.
Buy stocks of bariatric drugs
Is it a stock that makes you miss the real thing
It was bought out somewhere
I don't know if it will go up.
However, if approval is faster than Japan
I don't know if it's approved in the US.
Analysts evaluate buying and selling
There aren't many trial wins.
Why is there a lot of obesity in the world?
Now, Eli Lilly, Novo Nordisk
In order to invest with a high market capitalization, it has grown too much
Maybe it was too late to invest.
Has approval been granted? Before you know it,
Is it a scary stock that will go down even if it goes up?